Patients who have experienced compulsive behaviors resulting in financial losses and psychological damages after taking Abilify may be eligible to pursue a claim and seek financial compensation.
Abilify is an antipsychotic drug used to treat schizophrenia and manic depression. It has also been used off-label for dementia, autism, insomnia, and eating and mood disorders. After reviewing more than 100 cases, FDA issued a warning that the drug causes compulsive behaviors including gambling, shopping, and uncontrollable eating and sexual urges. As a result, more than 1,600 lawsuits have been filed against Abilify’s manufacturer, Otsuka America Pharmaceutical Inc., alleging that it knew about Abilify’s serious and life-changing side effects and failed to warn the public.
If you or a loved one took Abilify and suffered from compulsive gambling and other impulsive behaviors, contact Maxwell Law Group LLP today. We can answer your questions and review your case for free.
What is Abilify?
Abilify (generic name: aripiprazole) is an antipsychotic medication used to treat patients with schizophrenia, manic and mixed episodes of bipolar I disorder, major depressive disorder, irritability associated with autistic disorder, and Tourette’s disorder. FDA approved the drug in 2002 initially for schizophrenia and bipolar I disorder, adding other uses for Abilify in 2014.
Aside from its FDA approved uses, Abilify has been prescribed for dementia-induced psychosis in the elderly, aggression in autism patients, sleeplessness, eating disorders, and mood swings.
Abilify is manufactured by Otsuka America Pharmaceutical Inc. and marketed to the US by Bristol-Myers Squibb. In 2014, it was reported that Abilify became the best-selling drug in the US, with $7 billion in sales annually.
Abilify Quick Facts
Medication for schizophrenia and manic depression
Otsuka America Pharmaceutical Inc. and Bristol-Myers Squibb
How Does Abilify Work?
Similar to other atypical antipsychotics, the exact mechanism of action of Abilify is not yet clear. It has been established that it differs from other medications due to its action as an agonist of some dopamine and serotonin receptors, as opposed to purely inhibiting all D2 receptors. It has been theorized that altered dopamine levels in the brain result in schizophrenia.
Risks and Warnings
Abilify’s warnings and precautions include the following:
- Risk of stroke among elderly patients with dementia-related psychosis
- Neuroleptic malignant syndrome (fever, altered mental status, and muscle rigidity)
- Tardive dyskinesia
- Hyperglycemia and diabetes
- Weight gain
- Orthostatic hypotension
- White blood cell count abnormalities
- Seizures and convulsions
- Potential for motor and cognitive impairment
- Possibility of suicide
In 2005, the FDA issued a black box warning about the increased risk of mortality among elderly patients with dementia-related psychosis, and suicidal thoughts and behaviors among children, adolescents, and young adults, which were associated with Abilify use.
Moreover, in 2016,
Injuries from Abilify
A study conducted in 2013 showed that there is a possibility that aripiprazole (Abilify) causes pathological gambling. Data on 8 patients suffering from schizophrenia and bipolar disorder who were taking Abilify were analyzed. All of them had a history of addictive disorders and gambled regularly prior to being given a prescription of the drug. The study showed causaulity between Ability and problematic gambling in 7 of the patients, which the results were inconclusive for the final patient.
Another study published in 2014 in the Journal of the American Medical Association concluded that dopamine receptor agonists—including aripiprazole (Abilify)—were associated with impulse-control disorders. The study analyzed over 2.7 million drug events from 2003 to 2012, and identified 1,580 incidences related to impulse control disorders, specifically pathological gambling, hypersexuality, and compulsive shopping. Pathological gambling was mentioned in 628 (39.7%) of the reports.
In addition, a study from 2017 published in the Journal of Clinical Psychopharmacology confirmed the link between impulse control and gambling disorders and aripiprazole, among other drugs. An analysis of 355 gambling disorder cases and 4,341 cases of impulse-control disorder was conducted. Aripiprazole users showed the highest risk ratio for gambling and impulse-control disorders compared to pramipexole and ropinirole (although those two drugs also showed an elevated risk of these behaviors).
Currently, there are more than 2,300 pending lawsuits against Otsuka America Pharmaceutical, Inc. and Bristol-Myers Squibb on the grounds that these companies knew about the increased risk of compulsive and addictive behavior from using Abilify and failed to warn the public about these risks. Label changes about this risk were added in Europe back in 2012 and in Canada in 2015.
Bristol-Myers Squibb had paid settlements in the past: in 2007, the company paid a total of $515 million following a federal investigation where the company made payments to health care providers for prescribing Abilify for off-label uses; similar arrangements were made for pharmacies that filled the prescriptions.
Another settlement occurred in 2016 in the amount of $19.5 million for illegal marketing practices. The company continued to market the drug to elderly patients with dementia despite the FDA releasing a report that mortality is increased when these individuals use the medication. The company also promoted Abilify among children without any approval that it is indeed safe and effective for pediatric patients afflicted with psychological disorders.
In October 2016, pending cases were consolidated into multidistrict litigation (MDL) filed in the US District Court Northern District Florida. Patients who suffered from compulsive behaviors and their families affected by the drug’s serious risks are seeking damages for financial losses, medical expenses, and other psychological issues.
On February 15, 2019, Bristol-Myers Squibb and Otsuka America Pharmaceutical announced a global settlement for all claims filed up to January 28, 2019.
How Maxwell Law Group Can Help
If you or your loved one have engaged in compulsive behaviors after taking Abilify, Maxwell Law Group can help get you the compensation you deserve. Call (844) 525-7155 or fill out the form below and we’ll investigate your case at no charge to you.
You Deserve to be Compensated
We're On Your Side
Our attorneys are always ready to speak with you about your personal situation. Every day we help people in situations similar to yours. Our team can guide you each step of the way and make sure you get the financial compensation you deserve.
While our physical offices are in Utah and Washington DC, we offer our services nationwide. We'd be honored to discuss your case with you free of charge.
Please note that the law limits the time you have to pursue a claim or file a lawsuit for an injury. If you think you have a case, don't wait to take action. Contact us today.
To speak with us directly, call (844) 525-7155. We want to hear about your situation and help you through this difficult time.
ATTORNEY ADVERTISING. Nothing on this site should be taken as legal advice for any individual case or situation. This website is not intended to create, and receipt of viewing does not constitute, an attorney-client relationship. Sensitive information should not be submitted through this website as it may be considered confidential or privileged. References to prior results do not guarantee a similar outcome. The firm has attorneys licensed to practice law in Utah and Washington D.C., but the attorneys may also be admitted on an individual basis in additional state and federal courts across the United States. The location of the firm's offices are listed on this website. The firm associates with co-counsel law firms to jointly represent clients in some matters. Gregory Maxwell is the attorney responsible for the contents of this website.